This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Shire Pharmaceuticals (SHP.L) - AbbVie's chief executive has sought to quash any doubts that AbbVie would go through with its acquisition of Shire in the wake of the Treasury's proposed changes to U.S. inversion rules. Closing price 5365p. (Wall St. Journal)
Royal Bank of Scotland (RBS.L) - Says now expects to significantly outperform its previous guidance of £1bn in total impairments. Closing Price 361.40p (CNBC)
Next (NXT.L) - Will have to lower its full-year profit forecast if the country's unusually warm autumn weather continues. Closing Price 6865.00p (Reuters)
ICAP (IAP.L) - Said first-half revenue was expected to be 10 percent lower than a year earlier as low levels of volatility kept trading volumes suppressed. Closing price 395.7p. (Reuters)
Wolseley (WOS.L) - Posted a 8.6% rise in annual profit (£761m v £750m expected by analysts), said it would hike its dividend by 25% and would launch a £250m share buyback after strong U.S. trading. Closing price 3257p. (Reuters)
Saga (SAGA.L) - H1 group profit before tax on a like-for-like basis up 14.9% to £106.5m (2013: £92.7m) H1 profit before tax, after IPO expenses and one-off cost of new debt, of £32.8m (2013: £92.1m. Strong cash generation leading to a reduction in net debt ratio from 3.1 at initial public offering to 2.5 as at end H1. Closing Price 172.20p (Reuters)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| Standard Chartered | STAN.L | -1.62% | -0.04% | -2.68% |
| Royal Bank of Scotland | RBS.L | -0.30% | 0.50% | -0.99% |
| Tesco | TSCO.L | -1.48% | 0.34% | -2.63% |
| Balfour Beatty | BBY.L | -15.30% | -14.90% | -25.26% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research